Agios Pharma Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as First Disease-modifying Treatment for Patients with PKR #EHA2017
June 24, 2017 at 16:54 PM EDT
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) presented updated data from its wholly owned pyruvate kinase-R (PKR) activator ...
